Andrew Shiau

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

San Diego, CA (US) (2009 - 2022)
La Jolla, CA (US) (2023)

Company Filing History:

Ludwig Institute for Cancer Research Limited

patents

1 out of 449

Alcon Laboratories, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11612604 - Methods of treating cancer with PLK4 inhibitors (2023-03-28),

2. 11253521 - 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators (2022-02-22),

3. 10752612 - PLK4 inhibitors (2020-08-25),

4. 9078887 - Bicyclic heteroaryl inhibitors of PDE4 (2015-07-14),

5. 8258154 - Bicyclic heteroaryl inhibitors of PDE4 (2012-09-04),

6. 8138205 - Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 (2012-03-20),

7. 8080563 - Bicyclic heteroaryl inhibitors of PDE4 (2011-12-20),

8. 7915253 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR (2011-03-29),

9. 7834004 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR (2010-11-16),

10. 7745646 - Bicyclic heteroaryl inhibitors of PDE4 (2010-06-29),

11. 7494999 - Sulfonyl-substituted bicyclic compounds as modulators of PPAR (2009-02-24),

Title: **Innovator Andrew Shiau: Pioneering Cancer Treatment Solutions**

Introduction

Andrew Shiau, a prominent inventor based in San Diego, CA, has made significant strides in medical and pharmaceutical research. With a portfolio of 11 patents, he has dedicated his career to developing innovative solutions for pressing health issues, particularly cancer treatment.

Latest Patents

Among his most recent patents is a groundbreaking methodology for treating cancer through the use of PLK4 inhibitors. This discovery outlines various compounds and methods to inhibit PLK4, aiming to offer therapeutic options for individuals battling cancer. Another notable patent focuses on 3-hydroxy-quinazoline-2,4-dione derivatives, which are described as compounds that can modulate essential nucleases such as flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1), and/or GEN1.

Career Highlights

Shiau's professional journey is marked by his contributions to renowned organizations such as Kalypsys, Inc. and the Ludwig Institute for Cancer Research Limited. His work in these institutions has significantly impacted the field of cancer research, showcasing his commitment to advancing medical science through innovative inventions.

Collaborations

Throughout his career, Andrew has collaborated with esteemed coworkers, including Stewart Alwyn Noble and Steven P Govek. These partnerships emphasize the collaborative nature of scientific research and the importance of teamwork in fostering innovation.

Conclusion

In conclusion, Andrew Shiau stands out as a dedicated inventor whose contributions to cancer treatment through his patented methodologies and compounds demonstrate the potential of innovation in the medical field. His efforts not only advance scientific understanding but also bring hope to those affected by cancer, reflecting the transformative power of invention.

This text is generated by artificial intelligence and may not be accurate.